VSTM
- Verastem, Inc.
()
Overview
Company Summary
Verastem, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative drugs to address the needs of patients with cancer. The company primarily operates in the field of oncology, with a strong emphasis on targeting cancer stem cells and the tumor microenvironment.
Verastem aims to develop novel therapies that can potentially improve outcomes for cancer patients, especially those with difficult-to-treat forms of cancer. The company's diverse pipeline includes both small molecule drugs and targeted therapies, which are aimed at inhibiting the growth and spread of cancer cells.
One of Verastem's notable products is Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma enzymes. Copiktra is approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).
In addition to Copiktra, Verastem is actively conducting research and development to expand its product portfolio. The company is exploring various potential therapeutics and combinations to target other forms of cancer, including mesothelioma, ovarian cancer, non-small cell lung cancer, and more.
Overall, Verastem, Inc. dedicates its efforts to advancing novel cancer treatments and addressing unmet medical needs through its research, development, and commercialization activities in the field of oncology.